BioSpace News Archive

Eterna Therapeutics Inc. announced that the Company has entered into a common stock purchase agreement for up to $10 million with Lincoln Park Capital Fund, LLC.

Akari Therapeutics, Plc announced that management team representatives will attend ARVO 2023, the annual meeting of The Association for Research in Vision and Ophthalmology to meet with researchers, thought leaders, and potential partners.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer.

eFFECTOR Therapeutics, Inc. announced a clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine, who will serve as principal investigator in an investigator-initiated trial evaluating zotatifin in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in a pre-operative setting.

Chinook Therapeutics, Inc. today announced that dosing in the phase 1 clinical trial of CHK-336 in healthy volunteers has been voluntarily paused to allow a thorough investigation of a serious adverse event (SAE) that occurred in a single subject following the first dose in the 125 mg multiple ascending dose (MAD) group.

Impel Pharmaceuticals announced that four Trudhesa® nasal spray abstracts have been selected to be presented at the upcoming American Academy of Neurology Annual Meeting taking place in Boston, MA, April 22-27, 2023.

Avalyn Pharma Inc. reported top-line results from the company’s ongoing open-label extension trial for investigational drug AP01.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “ Process for Preparation of Biologically Active Copolymer ,” with expiry in 2041.

Pharming Group N.V. announces the first commercial shipments of Joenja® to patients in the United States.

A clinical-staged proprietary platform technology biotech company Genexine and its Asian regional partner, KG Bio unveiled the interim results of phase 3 clinical trial of GX-E4, a candidate for CKD induced anemia.